Sanofi, Regeneron broaden alliance to find their next Dupixent

AI Summary

Sanofi and Regeneron have expanded their alliance to develop long-acting antibody drugs targeting the same pathways as their anti-inflammatory blockbuster Dupixent. The deal includes a $1 billion upfront payment.

The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.